FDA Proposes Higher Standards For Fast-Tracked Cancer Meds

story
Image copyright: reuters

The Facts

  • The US Food and Drug Administration (FDA) is considering policy changes that could require drug makers to conduct more stringent trials to win fast-track approvals of cancer drugs.

  • The FDA’s proposed recommendation comes amid wide criticism of the agency's accelerated approval pathway and a federal investigation into its approval of Biogen Inc.'s Alzheimer's treatment Aduhelm.

Show more

The Spin

Establishment-critical narrative

The FDA has been engaged in blatant drug approval corruption for a long time, with one of the most recent examples being its “warp speed” approval of the COVID vaccines. This negligence runs deep, as the FDA has a history of not properly overseeing a wide range of clinical trials and not adequately publishing any errors. The FDA’s entire process endangers public health and is unacceptable.

The BMJ

Pro-establishment narrative

Some critics say the FDA approves drugs too quickly, while others say the agency works too slowly. The truth is that the FDA independently analyzes each medication and its clinical trial while weighing the impact of a treatment reaching the market. For oncology drugs, speed to market is a life-or-death matter, and the FDA knows that. In other cases, the FDA can take its time conducting trials. Overall, the agency takes a pragmatic approach to its regulatory process.

Google Books

Articles on this story